Tandutinib HCl (MLN-518, CT-53518) is a novel, potent and selective FLT3 antagonist with IC50 of 0.22 μM, it also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. Tandutinib has potential antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.

纯度：≥98%

CAS：387867-13-2 (free base)